Related Experiment Video
Updated: Dec 24, 2025
Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease
Published on: June 17, 2013
Disease Progression-Dependent Expression of CD200R1 and CX3CR1 in Mouse Models of Parkinson's Disease
Le Wang1, Yang Liu1, Shuxin Yan1
11Department of Neurobiology, Center of Parkinson Disease Beijing Institute for Brain Disorders, Beijing Key Laboratory on Parkinson Disease, Key Laboratory for Neurodegenerative Disease of the Ministry of Education, Beijing Key Laboratory of Neural Regeneration and Repair, Capital Medical University, Beijing, China.
Abstract:
Microglial activation is an important contributor to the pathogenesis of Parkinson's disease (PD). Microglia are tightly and efficiently regulated by immune checkpoints, including CD200-CD200R1 and CX3CL1-CX3CR1. Understanding the involvement of these checkpoints in disease progression provides important insights into how microglial activation contributes to PD pathology. However, so far, studies have produced seemingly conflicting results. In this study, we demonstrate that CD200R1 expression is down-regulated at both early and late stage of PD model, and CX3CR1 expression is down-regulated in early stage and recovered in late stage. In primary cultured microglia, CD200R1 and CX3CR1 expressions are both directly regulated by LPS or α-synuclein, and CD200R1 expression is more sensitively regulated than CX3CR1. In addition, CD200 knockout causes an increase in proinflammatory cytokine production and microglial activation in the midbrain. Remarkably, DA neurons in the substantial nigra are degenerated in CD200-/- mice. Finally, activation of the CD200R with CD200Fc alleviates the neuroinflammation in microglia. Together, these results suggest that immune checkpoints play distinct functional roles in different stage of PD pathology, and the CD200-CD200R1 axis plays a significant role in nigrostriatal neuron viability and function.
Insights
Immune checkpoints like CD200-CD200R1 are crucial in Parkinson's disease (PD) pathology. Targeting the CD200-CD200R1 axis may protect against neuroinflammation and neuron loss in PD.
Area of Science:
- Neuroimmunology
- Neurodegenerative Diseases
- Parkinson's Disease Pathogenesis
Background:
- Microglial activation significantly contributes to Parkinson's disease (PD) pathogenesis.
- Immune checkpoints, such as CD200-CD200R1 and CX3CL1-CX3CR1, regulate microglial activity.
- Previous studies on these checkpoints in PD have yielded conflicting results.
Purpose of the Study:
- To investigate the distinct roles of CD200-CD200R1 and CX3CL1-CX3CR1 immune checkpoints in PD progression.
- To elucidate the regulatory mechanisms of these checkpoints in microglial activation by inflammatory stimuli.
- To assess the therapeutic potential of targeting the CD200-CD200R1 axis in PD.
Main Methods:
- Analysis of CD200R1 and CX3CR1 expression levels in a PD model at different disease stages.
- In vitro studies using primary cultured microglia exposed to lipopolysaccharide (LPS) or α-synuclein.
- Assessment of microglial activation, cytokine production, and dopaminergic neuron survival in CD200 knockout mice.
- Evaluation of the therapeutic effect of CD200Fc treatment on neuroinflammation.
Main Results:
- CD200R1 expression was downregulated in both early and late stages of PD, while CX3CR1 was downregulated early and recovered late.
- LPS or α-synuclein directly regulated CD200R1 and CX3CR1 expression in microglia, with CD200R1 showing higher sensitivity.
- CD200 knockout exacerbated midbrain microglial activation and proinflammatory cytokine production, leading to dopaminergic neuron degeneration.
- CD200Fc treatment alleviated neuroinflammation in microglia.
Conclusions:
- Immune checkpoints exhibit distinct functional roles during different stages of PD.
- The CD200-CD200R1 axis plays a critical role in maintaining nigrostriatal neuron viability and function.
- Targeting the CD200-CD200R1 pathway represents a potential therapeutic strategy for Parkinson's disease.
More Related Videos
14:45Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
